ADC Therapeutics Reports Positive Results from LOTIS-5 Trial for ZYNLONTA in Lymphoma Treatment
ADC Therapeutics has announced the results of its Phase 3 LOTIS-5 trial, which evaluated the efficacy of ZYNLONTA in combination with rituximab for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial demonstrated that the combination achieved statistical significance in progression-free survival (PFS), with a median PFS of 6.1 months compared to 4.7 months for the control group receiving standard immunochemotherapy. The overall response rate was higher for the ZYNLONTA combination, with 58.1% versus 45.2% for the control. Despite higher rates of serious adverse events in the test arm, the study showed no detrimental effect on overall survival. ADC Therapeutics plans to discuss the benefit-risk profile with the U.S. FDA as it prepares for a supplemental Biologics License Application. 
